Industry - onset.to

Yesterday October 30, 2026

FDA Approves NRx’s Preservative-Free Generic Ketamine, While Its Petition to Remove Rivals’ BZT Products Remains Pending

psychedelicalpha.com · Oct 30, 2026

Ketamine Article Business Industry Policy

October 28, 2026

Pharma Moves In: Investors, Developers and Lilly’s Carole Ho Discuss Psychedelic Drug Development at Healthcare Forum

psychedelicalpha.com · Oct 28, 2026

5-MeO-DMT Article Business Industry Research

October 26, 2026

Stakeholders Respond to the FDA’s Psychedelics Docket, Revealing Broad Support and Divisions Over Regulation, Therapy, and Trial Safeguards

psychedelicalpha.com · Oct 26, 2026

Article Industry Policy Research

October 25, 2026

After a long, strange trip, Compass Pathways CEO Kabir Nath is close to bringing its psilocybin pill COMP360 to market

businessinsider.com · Oct 25, 2026

Psilocybin Article Business Clinical Industry

October 23, 2026

Before European Approvals: Norway, Germany, Switzerland, the UK and Estonia Build Psychedelic Access Pathways at TAIP 2026

psychedelicalpha.com · Oct 23, 2026 · Ryan Khan

Psilocybin Ketamine Article Clinical +2

October 21, 2026

Poacher Turned Gamekeeper: HHS’ Matt Zorn on Ibogaine, Right to Try and the Psychedelics Executive Order

psychedelicalpha.com · Oct 21, 2026 · Josh Hardman

Psilocybin Ibogaine Article Industry +2

October 20, 2026

Podcast: Early Healthcare Forum Takeaways, FDA’s Ibogaine Blueprint, and Compass Talks Pricing

psychedelicalpha.com · Oct 20, 2026 · Josh Hardman

Psilocybin Ibogaine Podcast Clinical +2

October 19, 2026

Portier Psychedelics Cases: Wie Design, Sicherheitswissen und Community psychedelische Rituale bewusster gestalten

lucys-magazin.com · Oct 19, 2026

Psilocybin DMT Article HarmReduction +2 DE

October 16, 2026

Lilly neuroscience president says the company is interested in studying and improving ibogaine through research and development

endpoints.news · Oct 16, 2026

Ibogaine Article Business Industry Research

October 15, 2026

Compass Pathways CEO says psychedelic therapy company will proceed cautiously before accelerating its growth

statnews.com · Oct 15, 2026 · Meghana Keshavan

Article Business Industry Policy

Solvonis Therapeutics investor webinar on SVN-001, addiction treatment and mental health development milestones

vimeo.com · Oct 15, 2026 · Anthony Tennyson, Professor David Nutt, Barry Gibb

Podcast Business Clinical Industry

October 14, 2026

The Psychedelic Practitioner Issue 7: Preparedness and the Systems Needed to Deliver Psychedelic Therapies

psychedelicalpha.com · Oct 14, 2026 · Alice Lineham and Josh Hardman

Psilocybin MDMA Article Clinical +2

Big Pharma herontdekt psychedelica als medicijn: overname van Atai Beckley toont groeiende marktverwachtingen

nrc.nl · Oct 14, 2026 · Philippus Zandstra

Psilocybin 5-MeO-DMT Article Industry +2 NL

October 9, 2026

Crowdfunding für das Grundlagenwerk "Musik in der psychedelischen Therapie" läuft nur noch einen Tag

lucys-magazin.com · Oct 9, 2026

Article Industry Music Therapy DE

October 8, 2026

Helus Pharma kündigt Investorenpräsentation zu HLP003 und HLP004 für Depressionen und Angststörungen am 21. Oktober 2026 an

ir.helus.com · Oct 8, 2026

Article Business Industry Research DE

October 5, 2026

Psyence signs a US ibogaine manufacturer, but DEA approvals, import limits, quotas, and clinical filings remain unresolved

behavioralwire.com · Oct 5, 2026 · Editorial Desk

Ibogaine Article Industry Policy Research

Podcast: Oregon abandons psilocybin fee hike as California funds research and DEA again moves to schedule five tryptamines

psychedelicalpha.com · Oct 5, 2026 · Josh Hardman

Psilocybin Podcast Industry Policy Research

October 2, 2026

Is HHS too cosy with the psychedelic industry, and is the public being misled about psychedelic risks?

ecstaticintegration.org · Oct 2, 2026 · Jules Evans

LSD Psilocybin Article Industry +2

September 30, 2026

DEA proposes Schedule I status for five tryptamines as Oregon drops psilocybin fee hikes and GAO questions scheduling procedures

psychedelicstoday.com · Sep 30, 2026 · Jack Gorsline

Psilocybin Article Industry Policy Research

Kritik am »psychedelischen Kapitalismus«: Buchbesprechung hinterfragt die Kommerzialisierung von Psychedelika

psychedelia-stiftung.de · Sep 30, 2026

Article Culture Ethics Industry DE

September 26, 2026

Kapitalismus-Crash, Cash und Psychedelika: Investor Christian Angermayer über Exit, Gehirnchips und Bitcoin

welt.de · Sep 26, 2026 · Holger Zschäpitz, Nando Sommerfeldt, WELT

Podcast Business Industry Mainstream DE

September 24, 2026

Psychedelische Tryptamine biotechnologisch in Pflanzen hergestellt: Plattform für gezielte Biosynthese und Produktion

psychedelia-stiftung.de · Sep 24, 2026

Psilocybin DMT Article Industry +2 DE

September 23, 2026

DEA renews effort to place five psychedelic tryptamines in Schedule I as FDA research progress draws criticism from advocates

psychedelicamericas.org · Sep 23, 2026 · PSA Media Team, Jack Gorsline

Article Industry Policy Research

September 22, 2026

FDA hearing, VA psychedelic bill claims, and Alabama's marijuana rescheduling objection shape September 2026 policy briefing

psychedelicstoday.com · Sep 22, 2026 · Jack Gorsline

Psilocybin MDMA Article Industry +2

September 21, 2026

Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers

psychedelicalpha.com · Sep 21, 2026 · Josh Hardman

Ibogaine MDMA Podcast Industry +2